AstraZeneca’s “Neutral” Rating Reaffirmed at KBC Securities (AZN)
AstraZeneca (LON:AZN)‘s stock had its “neutral” rating reiterated by equities researchers at KBC Securities in a research report issued on Wednesday, AnalystRatingsNetwork.com reports. They currently have a GBX 3,300 ($51.59) price objective on the stock. KBC Securities’ price objective points to a potential upside of 5.31% from the stock’s previous close.
Shares of AstraZeneca (LON:AZN) opened at 3127.00 on Wednesday. AstraZeneca has a 1-year low of GBX 2786.00 and a 1-year high of GBX 3544.50. The stock’s 50-day moving average is GBX 3231. and its 200-day moving average is GBX 3243.41. The company’s market cap is £39.150 billion.
A number of other firms have also recently commented on AZN. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca (LON:AZN) in a research note to investors on Wednesday. They now have a GBX 3,300 ($51.59) price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of AstraZeneca (LON:AZN) from GBX 3,400 ($53.16) to GBX 3,200 ($50.03) in a research note to investors on Tuesday. They now have a “hold” rating on the stock. Finally, analysts at Morgan Stanley reiterated an “underweight” rating on shares of AstraZeneca (LON:AZN) in a research note to investors on Monday, September 2nd. They now have a GBX 3,200 ($50.03) price target on the stock.
Twelve equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the company. AstraZeneca currently has a consensus rating of “Hold” and a consensus price target of GBX 3,201.78 ($50.06).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.